

Holger STARK

Johann Wolfgang Goethe University Frankfurt am Main, Institute of Pharmaceutical Chemistry, Biozentrum, Max-von-Laue-Strasse 9, 60438 Frankfurt am Main, Germany

The identification of histamine H₃ (H₃R) receptors some time ago as an important subpopulation within the four histamine receptor subtypes known revived the interest in histamine research and exposed attractive perspectives for the potential therapeutic exploitation of these new drug targets. Meanwhile novel lead optimizations for histamine H₃ receptor antagonists made their way from an early stage already into the clinics [1]. Whereas in the beginning the main structures have been imidazole-based, the newer developments belong to different non-imidazole structural classes. Useful pharmacological tools with additional physicochemical properties, e.g. fluorescence, or pharmacodynamic profiles, e.g. multiple targeting, can be drawn to limited variations of some pharmacophore blue-prints [2]. Structure-activity relationships, cross-affinities and side effects as well as pharmacokinetic profiling will be discussed on selected promising compound series [3]. The H₃R is a recognised drug target for neuronal diseases, such as cognitive impairment, schizophrenia, sleep-wake disorders, epilepsy and neuropathic pain and a small number of selective H₃R antagonists have already passed some clinical phase II trials. Due to diversity in potential therapeutic applications and in some cases a controversial debate, different indications will be highlighted with the potential and the problems of the test compounds, e.g. sleep-wake disorders, ADHD, epilepsy, cognitive impairment, schizophrenia, obesity and neuropathic pain. Some of the most promising compounds so far are PF-3654746, SAR-110894, JNJ-31001074, SCH-497079, HPP-404 and tiprolisant. First data published on clinical trials phase II (IIb) are presented showing proof of concept of H₃ receptor antagonists in narcolepsy and photo-induced epilepsy [4].

Supported by the ESF-COST Action BM0806 and the LOEWE – LiFF consortium.

[1] S. Celanire, F. Lebon, H. Stark. Drug Discovery: From Hits to Clinical Candidates. The Third Histamine Receptor: Selective Ligands as Potential Therapeutic Agents in CNS Disorders (ed. D. Vohora), CRC Press, Taylor & Francis CRC Press Inc., Boca Raton, Fla/USA., **2009**, pp. 103-165.

[2] Y. von Coburg, T. Kottke, L. Weizel, X. Ligneau, H. Stark. Potential Utility of Histamine H₃ Receptor Antagonist Pharmacophore in Antipsychotics. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 538-542.

[3] K. Sander, T. Kottke, H. Stark. Histamine H₃ Receptor Antagonists Go to Clinics. *Biol. Pharm. Bull.* **2008**, *31*, 2163-2181.

[4] E. Tiligada, E. Zampeli, K. Sander, H. Stark. Histamine H₃ and H₄ Receptors as Novel Drug Targets. *Expert Opin. Invest. Drugs* **2009**, *18*, 1519-1531.